Physician profile
Eric A Dohner
NPI 1801869821
$3,707.00
in general payments reported to CMS, 2019-2025
26 companies · $529 in 2025
The $529 reported for 2025 was more than what 79% of Phlebology providers received nationally (typical 2025 total: $141).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,061 · 2020: $193 · 2021: $518 · 2022: $381 · 2023: $586 · 2024: $439 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,554.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $969.12 | 2019-2025 | Skyrizi |
| Merz North America, INC. | $661.47 | 2019-2023 | |
| Lilly USA, LLC | $306.32 | 2019-2024 | Taltz, Olumiant |
| Sun Pharmaceutical Industries INC. | $276.61 | 2022-2025 | |
| Incyte Corporation | $225.71 | 2022-2023 | Opzelura |
| Genzyme Corporation | $191.17 | 2021-2025 | |
| Janssen Biotech, INC. | $168.07 | 2019-2025 | Tremfya, Remicade, Simponi |
| Janssen Scientific Affairs, LLC | $116.94 | 2019 | |
| Pfizer INC. | $110.90 | 2019-2023 | |
| Allergan, INC. | $105.63 | 2019-2022 | |
| Galderma Laboratories, L.P. | $104.43 | 2019-2025 | Dysport |
| Medtronic, INC. | $56.84 | 2022-2023 | Closurefast, Venaseal |
| Ucb, INC. | $54.40 | 2023-2025 | Cimzia, Bimzelx |
| Amgen INC. | $42.65 | 2019-2024 | Otezla |
| Boston Scientific Corporation | $41.42 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $37.66 | 2019 | |
| Tactile Systems Technology INC | $36.17 | 2019 | |
| Novo Nordisk INC | $29.09 | 2019-2021 | |
| Organogenesis INC. | $28.05 | 2024 | |
| Fidia Pharma USA INC. | $27.41 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $27.17 | 2021 | |
| Abbott Laboratories | $22.25 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $19.72 | 2019 | |
| Medtronic Vascular, INC. | $19.66 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.59 | 2020 | |
| Biofrontera INC. | $13.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Dohner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.